entertainment -WSS

entertainment

author：fashion 2025-10-02 22:28:24 - browse：7618

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Johnson & Johnson sued for allegedly overpaying for workers' drugs

WSS

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Gene therapy for Afghan refugees’ infant will be fully covered

Dogs on Prozac: What pet anti

Cell therapy fails to slow type 1 diabetes, but safety is established

Dogs on Prozac: What pet anti

Bird flu in milk supply is likely coming from asymptomatic cows

leisure time

entertainment

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Cue Health's Covid

Dobbs anniversary: the lost opportunity of abortion as health care

H5N1 bird flu found in pasteurized milk: what we know

Novavax promises a turnaround & Lilly roils the obesity market

Melinda French Gates resigns from Gates Foundation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gene therapy for Afghan refugees’ infant will be fully covered

leisure time

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Readout LOUD: Venture capital, Gilead, and more M&A

Diversity in clinical trials starts with building trust, experts say

Why Novartis is going to walk from its acquisition of MorphoSys

Problems with a popular proposal to regulate AI in health care

What’s missing from the debate over nursing home staff minimums

leisure time

leisure time

focus

hotspot